EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta‐Analysis

Hammad Javaid, Maria Qadri, Hameer Ali, Chika Franklin Chilaka, Wajiha Syed, Erum Habib, Fahmida Zahin, Ayaan Musani, Salauddin Ali Khan, Daniah Rizwan, Muhammad Nabeel Saddique, Fatima Hajj

eJHaem · 2026-04 · 7 (2)

DOI: 10.1002/jha2.70294 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift eJHaem, online erschienen am 24.04.2026. Verfasst von Hammad Javaid und 11 weiteren Autor:innen. Beteiligte Einrichtung: King Edward Medical University Lahore Pakistan. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life‐threatening disorder characterized by complement‐mediated hemolysis. Crovalimab, a novel anti‐C5 monoclonal antibody, may offer a more convenient alternative to current therapies, highlighting the need for a comprehensive analysis of its efficacy and safety.

Methods

A comprehensive search was conducted through PubMed, Embase, Cochrane, and clinicaltrials.gov using relevant keywords from inception until January 2025. Statistical calculation was conducted using MetaXL 5.3 by employing a random effects model to estimate the pooled event rates with 95% CI. Heterogeneity was assessed using the I 2 and χ 2 statistics.

Results

This meta‐analysis included four studies involving 275 patients with a mean age of 41.87 ± 13.34 years with rate of hemolysis control of 86% (95% CI: 77%–94%, I 2 = 73%) and transfusion avoidance in 77% of patients (95% CI: 56%–93%, I 2 = 90%), breakthrough hemolysis of 10% (95% CI: 6%–13%, I 2 = 0%) and hemoglobin stabilization in 69% patients (95% CI: 43%–90%, I 2 = 98%). The incidence rate of any adverse event was 89% (95% CI: 76%–98%, I 2 = 87%) and serious adverse events 15% (95% CI: 7%–25%, I 2 = 74%).

Conclusion

We observed high rates of hemolysis control and transfusion avoidance but significant adverse events. Study heterogeneity and publication bias limit generalizability, highlighting the need for larger, more robust trials. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission

Schlagwörter

Stichwörter der Autor:innen

crovalimabmeta‐analysismonoclonal antibodyparoxysmal nocturnal hemoglobinuria

Autor:innen und Institutionen

  • King Edward Medical University Lahore Pakistan.
  • Jinnah Sindh Medical University Karachi Pakistan.
  • Chandka Medical College Larkana Pakistan.
  • Robert Wood Johnson University Hospital New Brunswick New Jersey USA.
  • Harvard Medical School Boston Massachusetts USA.
  • Dow University of Health Sciences Karachi Pakistan.

Zitieren

APA

Javaid, H., Qadri, M., Ali, H., Chilaka, C. F., Syed, W., Habib, E., Zahin, F., Musani, A., Khan, S. A., Rizwan, D., Saddique, M. N., & Hajj, F. (2026). Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta‐Analysis. eJHaem, 7(2). https://doi.org/10.1002/jha2.70294

Vancouver

Javaid H, Qadri M, Ali H, Chilaka CF, Syed W, Habib E, et al. Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta‐Analysis. eJHaem. 2026;7(2). doi:10.1002/jha2.70294

BibTeX
@article{Javaid2026,
  author = {Javaid, Hammad and Qadri, Maria and Ali, Hameer and Chilaka, Chika Franklin and Syed, Wajiha and Habib, Erum and Zahin, Fahmida and Musani, Ayaan and Khan, Salauddin Ali and Rizwan, Daniah and Saddique, Muhammad Nabeel and Hajj, Fatima},
  title = {Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta‐Analysis},
  journal = {eJHaem},
  year = {2026},
  volume = {7},
  number = {2},
  doi = {10.1002/jha2.70294}
}
Kostenlos starten →